CatalYm is a biopharmaceutical company developing novel cancer immunotherapies targeting Growth-and-Differentiation Factor 15 (GDF-15). Apart from its established role in cachexia, GDF-15 has been associated with immunosuppression in tissues and tumors and a rapidly growing body of literature supports the concept that GDF-15 is a major T cell repellent. CatalYm aims to neutralize GDF-15 to turn “cold” tumors “hot” and thereby substantially improving the efficacy of established immunotherapy such as anti-PD1/-PD-L1 checkpoint inhibitors. The company’s lead product candidate CTL-002, a neutralizing GDF-15 antibody, is set to enter clinical development in 2020.
Location: Germany, Bavaria, Planegg
Employees: 11-50
Total raised: $261.12M
Founded date: 2016
Investors 8
| Date | Name | Website |
| - | Vesalius B... | vesaliusbi... |
| 16.04.2022 | Jeito Capi... | jeito.life |
| - | BioGenerat... | biogenerat... |
| 01.07.2025 | Omega Fund... | omegafunds... |
| 09.01.2023 | Brandon Ca... | brandoncap... |
| 09.09.2022 | Forbion | forbion.co... |
| - | Coparion | coparion.v... |
| 26.07.2024 | Bioqube Ve... | bioqubeven... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.09.2024 | Series D | $150M | - |
| 24.11.2022 | Series C | $52.03M | - |
| 11.11.2020 | Series B | $59.09M | - |
Mentions in press and media 28
| Date | Title | Description |
| 16.09.2025 | CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development | Experienced executives, Clinton Musil, Sujata Rao, MD, Heike Krupka, PhD, and Andrea Goddard join CatalYm to broaden and accelerate clinical programs into late-stage development Munich, Germany and San Francisco, USA, September 15, 2025 – C... |
| 28.07.2025 | Brandon Capital: Fund Six Closed At Over A$439 Million | Brandon Capital, Australasia’s leading life sciences venture capital firm, has announced the final close of its sixth fund, the Brandon BioCatalyst Fund Six (BB6), totaling A$439 million. New investors in BB6 include the Western Australia G... |
| 12.05.2025 | CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025 | MUNICH–(BUSINESS WIRE)–CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug conjugates (ADCs). The da... |
| 25.04.2025 | CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025 | Munich, Germany, April 25, 2025 – CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug conjugates (AD... |
| 15.01.2025 | CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab | Munich, Germany and San Francisco, USA, January 09, 2025 – CatalYm today announced the appointment of Scott Clarke as Chief Executive Officer. Mr. Clarke brings over two decades of executive leadership experience in driving company growth, ... |
| 11.12.2024 | CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference | MUNICH– CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, visugromab, to mitigate cancer cachexia by neutralizing the G... |
| 21.10.2024 | Despite faltering VC funding in Europe, healthtech made a comeback in Q3 | European startup funding faltered in Q3 2024, with startups raising a total of $11.3 billion – down 35% compared to the same time last year according to Dealroom. However, total investment in European tech so far in 2024 totals $40.9 billio... |
| 07.09.2024 | CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab | Munich, Germany, July 16, 2024 – CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunit... |
| 28.07.2024 | CatalYm's $150 Million Bet on Cancer Resistance: A New Dawn in Immunotherapy | In the relentless battle against cancer, CatalYm has emerged as a beacon of hope. The Munich-based company recently secured $150 million in Series D funding, a significant leap forward in its mission to combat cancer therapy resistance. Thi... |
| 27.07.2024 | CatalYm: Cancer Therapy Resistance Mechanism Company Raises $150 Million In Series D | CatalYm announced the completion of a $150 million Series D financing. The oversubscribed funding round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde... |
Show more